Slideshows

Sep 26, 2017

B-cell malignancies are among the most deadly and difficult-to-treat blood disorders. Our understanding of treatment options, prognostic indicators, and value in B-cell malignancies is constantly evolving. Within the past 6 months, there have been numerous breakthroughs in B-cell malignancy therapies, biomarkers, prognoses, and mutational understandings. Review the late breakthroughs in this field since the early summer. 

Aug 18, 2017

Ovarian cancer is one of the leading causes of cancer death among women in the United States. Our understanding of treatment options, prognostic indicators, and value in ovarian cancer is constantly evolving. Review the latest research breakthroughs involving ovarian cancer therapies, biomarkers, prognoses, surgical outcomes, and personalized treatment.

Aug 11, 2017

Chimeric antigen receptor (CAR) T-cell therapy is a rapidly evolving immunotherapy approach to treating various blood cancers and hematologic malignancies. Review the latest research breakthroughs involving CAR-T therapy in disease settings such as acute lymphoblastic leukemia, multiple myeloma, and chronic lymphocytic leukemia.
 

May 09, 2017

The US Food and Drug Administration (FDA) has approved many new drugs and indications for the treatment of cancer in the last 6 months. Review the drugs that were approved to treat specific forms of blood cancer and the results that led to the FDA decisions.
 

Aug 31, 2016

The Food and Drug Administration (FDA) approved more than 20 new drugs and indications for the treatment of cancer in the last year. Review the drugs that were approved to treat specific forms of lung cancer and the results that led to the FDA decisions.